Minimum alveolar concentration

IRADIMED CORPORATION to Hold 2022 Third Quarter Financial Results Conference Call on November 3rd

Retrieved on: 
Thursday, October 27, 2022
Company, NASDAQ, Field line, Human, Temperature, Radio, Communication, Patient, Travel, Vital signs, GLOBE, CO2, MRI, Internet, Minimum alveolar concentration, Time, ECG, Oxygen saturation (medicine), Online shopping, Medical imaging

WINTER SPRINGS, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION(NASDAQ: IRMD) announced today that the Company will release its 2022 third quarter financial results before the market opens on Thursday, November 3rd.

Key Points: 
  • WINTER SPRINGS, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION(NASDAQ: IRMD) announced today that the Company will release its 2022 third quarter financial results before the market opens on Thursday, November 3rd.
  • IRADIMEDhas scheduled a conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time Thursday, November 3, 2022.
  • Individuals interested in participating in the conference call may do so by registering here, https://register.vevent.com/register/BIcffe00ca21c54c31b6a2a7db74cb48ea .
  • IRADIMED CORPORATIONis a leader in the development of innovative magnetic resonance imaging (MRI) compatible medical devices.

IRADIMED CORPORATION Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA

Retrieved on: 
Monday, October 10, 2022
U.S. Securities and Exchange Commission, Time, Sale, Oxygen saturation (medicine), Anesthesia, NASDAQ, Patient, Human, Field line, Security (finance), MRI, Temperature, Company, Marketing, Magnetic resonance, Minimum alveolar concentration, GLOBE, Travel, Death, Vital signs, FDA, COVID-19, Radio, Magnetic resonance imaging, CO2, ECG, Medical device, Medical imaging

Roger Susi, President and Chief Executive Officer of the Company, commented, We have been engaged in several productive and positive discussions with the FDA.

Key Points: 
  • Roger Susi, President and Chief Executive Officer of the Company, commented, We have been engaged in several productive and positive discussions with the FDA.
  • It is important to note that this withdrawn 510(k) is for a future product and in no way affects our current revenue-generating product portfolio.
  • The Company also announced selected preliminary financial results for the third quarter ended September 30, 2022.
  • The IRADIMED 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and effectively communicates patient vital signs information to clinicians.

IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

Retrieved on: 
Thursday, October 6, 2022
Time, United States Department of Health and Human Services, Communication, Oxygen saturation (medicine), Bachelor of Science in Biomedical Engineering, Catholic higher education, Human services, Anesthesia, NASDAQ, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Program, Engineering, Human, Field line, Biomedical engineering, MRI, Device, Temperature, FDA Center for Devices and Radiological Health, Food, Company, Magnetic resonance, Industry, Department, National, Board, Medical device, GLOBE, Minimum alveolar concentration, Travel, Captain America, United States Public Health Service, Vital signs, Radio, Magnetic resonance imaging, CO2, ECG, Medical imaging, Science

WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION(the Company) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022.

Key Points: 
  • WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION(the Company) (NASDAQ: IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022.
  • Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent.
  • We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board, said Roger Susi, President and Chief Executive Officer of the Company.
  • The IRADIMED 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

IRADIMED CORPORATION Announces Second Quarter 2022 Financial Results

Retrieved on: 
Friday, July 29, 2022
MRI, Sale, Time, Human, Cyprus Securities and Exchange Commission, Temperature, Field line, Oxygen saturation (medicine), Travel, Marketing, COVID-19, Nature, Magnetic resonance imaging, GAAP, Vital signs, Magnetic resonance, Internet, FDA, Company, CO2, Security (finance), Patient, Radio, ECG, Minimum alveolar concentration, Death, Communication, Video game, Online gambling, Bank, Pharmaceutical industry, Risk management, Online shopping, Medical imaging

For the second quarter 2022, domestic sales were 85.0 percent of total revenue, compared to 82.0 percent for the first quarter 2021.

Key Points: 
  • For the second quarter 2022, domestic sales were 85.0 percent of total revenue, compared to 82.0 percent for the first quarter 2021.
  • Gross profit margin was 79.7 percent for the second quarter 2022, compared to 76.2 percent for the second quarter 2021.
  • Gross profit margin was 78.0 percent for the second quarter 2022, compared to 75.6 percent for the second quarter 2021.
  • All of our non-GAAP financial measures are important tools for financial and operational decision making and for evaluating our on-going core operating results.

IRADIMED CORPORATION to Hold 2022 Second Quarter Financial Results Conference Call on July 29th

Retrieved on: 
Friday, July 22, 2022
MRI, Time, GLOBE, Human, Temperature, Field line, Oxygen saturation (medicine), Travel, NASDAQ, Vital signs, Company, CO2, Patient, Radio, ECG, Minimum alveolar concentration, Communication, Internet, Online shopping, Medical imaging

WINTER SPRINGS, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th.IRADIMEDmanagement will host a conference call the same day beginning at 11:00a.m.

Key Points: 
  • WINTER SPRINGS, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 second quarter financial results before the market opens on Friday, July 29th.IRADIMEDmanagement will host a conference call the same day beginning at 11:00a.m.
  • The conference call will also be available real-time via the Internet at http://www.iradimed.com/en-us/investors/events/ .
  • A recording of the call will be available on the Companys website for 90 days following completion of the call.
  • IRADIMED CORPORATIONis a leader in the development of innovative magnetic resonance imaging (MRI) compatible medical devices.

IRADIMED Names John F. Glenn Chief Financial Officer

Retrieved on: 
Thursday, May 26, 2022
MBA, Vital signs, ECG, Company, Oxygen saturation (medicine), Minimum alveolar concentration, Magnetic resonance imaging, Patient, Human, MRI, NASDAQ, Reno 1868 FC, Santa Clara University, FDA, Accounting, Industry, Intermagnet, Time, Financial Executives International, Bausch Health, Communication, University, Travel, Field line, Temperature, Business administration, CO2, Acquisition, SEC, GLOBE, Management, Medical imaging

WINTER SPRINGS, Fla., May 26, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION(NASDAQ:IRMD), today announced that John (Jack) Glenn has been appointed Chief Financial Officer effective on or before June 20, 2022.

Key Points: 
  • WINTER SPRINGS, Fla., May 26, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION(NASDAQ:IRMD), today announced that John (Jack) Glenn has been appointed Chief Financial Officer effective on or before June 20, 2022.
  • Prior to serving as Chief Financial Officer at Esko Bionics, Mr. Glenn served as Chief Financial Officer for Sonendo, Inc., a privately-held, venture-backed company.
  • Jack is a seasoned financial executive with a strong background in the medical device industry and we are excited to have him join us as Chief Financial Officer.
  • His strategic financial management mindset will support IRADIMEDs continued strong growth trajectory, said Roger Susi, President and Chief Executive Officer of the Company.

IRADIMED CORPORATION Announces First Quarter 2022 Financial Results

Retrieved on: 
Friday, April 29, 2022
Oxygen saturation (medicine), Radio, Cyprus Securities and Exchange Commission, Time, MRI, Vital signs, Death, ECG, Sale, Patient, GAAP, FDA, Magnetic resonance imaging, COVID-19, Magnetic resonance, Travel, Company, CO2, Internet, Security (finance), Marketing, Communication, Nature, Temperature, Field line, Minimum alveolar concentration, Human, Bank, Risk management, Medical imaging

For the first quarter 2022, domestic sales were 81.1 percent of total revenue, compared to 78.8 percent for the first quarter 2021.

Key Points: 
  • For the first quarter 2022, domestic sales were 81.1 percent of total revenue, compared to 78.8 percent for the first quarter 2021.
  • Gross profit margin was 76.2 percent for the first quarter 2022, compared to 76.6 percent for the first quarter 2021.
  • These measures, which we refer to as our non-GAAP financial measures, are not prepared in accordance with U.S. GAAP.
  • All of our non-GAAP financial measures are important tools for financial and operational decision making and for evaluating our on-going core operating results.

IRADIMED CORPORATION to Hold 2022 First Quarter Financial Results Conference Call on April 29th

Retrieved on: 
Tuesday, April 5, 2022
Company, Temperature, NASDAQ, ECG, Internet, Human, CO2, Vital signs, Radio, Oxygen saturation (medicine), Communication, Travel, Minimum alveolar concentration, Time, GLOBE, Field line, MRI, Patient, Online shopping, Medical imaging

WINTER SPRINGS, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 first quarter financial results before the market opens on Friday, April29th.IRADIMEDmanagement will host a conference call the same day beginning at 11:00a.m.

Key Points: 
  • WINTER SPRINGS, Fla., April 05, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 first quarter financial results before the market opens on Friday, April29th.IRADIMEDmanagement will host a conference call the same day beginning at 11:00a.m.
  • Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering reservation code 3179386.
  • The conference call will also be available real-time via the Internet at http://www.iradimed.com/en-us/investors/events/ .
  • IRADIMED CORPORATIONis a leader in the development of innovative magnetic resonance imaging (MRI) compatible medical devices.

IRADIMED Announces Special $1.00 Per Share Cash Dividend

Retrieved on: 
Monday, February 7, 2022
Board of directors, NASDAQ, GLOBE, Growth, U.S. Securities and Exchange Commission, Death, Temperature, Time, Board, Company, Investment, Marketing, Sale, Human, FDA, Patient, ECG, Field line, Security (finance), Vital signs, Minimum alveolar concentration, Travel, Radio, MRI, Oxygen saturation (medicine), CO2, Communication, COVID-19, Medical imaging

WINTER SPRINGS, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- IRADIMEDCORPORATION (the Company) (NASDAQ: IRMD), announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Companys outstanding common stock.

Key Points: 
  • WINTER SPRINGS, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- IRADIMEDCORPORATION (the Company) (NASDAQ: IRMD), announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Companys outstanding common stock.
  • This special cash dividend is payable on February 24, 2022 to shareholders of record at the close of business on February 17, 2022.
  • With our strong financial results over the years and our ability to generate cash from operations, our cash balance grew to nearly $62 million at the end of 2021.
  • Therefore, the Board determined the best use of this excess cash is to return it to shareholders in the form of a special cash dividend, said Roger Susi, Chairman, President and Chief Executive Officer of the Company.

IRADIMED CORPORATION Announces Fourth Quarter 2021 Financial Results

Retrieved on: 
Friday, February 4, 2022
ECG, Patient, Field line, Sale, Communication, CO2, Death, Nature, Oxygen saturation (medicine), COVID-19, Marketing, MRI, Cyprus Securities and Exchange Commission, Human, Temperature, Company, Travel, Time, FDA, Minimum alveolar concentration, Security (finance), Internet, Vital signs, GAAP, Radio, Animal, Bank, Risk management, Medical imaging

For the fourth quarter 2021, domestic sales were 79.8 percent of total revenue, compared to 83.1 percent for the fourth quarter 2020.

Key Points: 
  • For the fourth quarter 2021, domestic sales were 79.8 percent of total revenue, compared to 83.1 percent for the fourth quarter 2020.
  • Gross profit margin was 77.9 percent for the fourth quarter 2021, compared to 75.3 percent for the fourth quarter 2020.
  • For the fourth quarter ended December 31, 2021, free cash flow was $3.3 million, compared to $2.4 million for the fourth quarter 2020.
  • All of our non-GAAP financial measures are important tools for financial and operational decision making and for evaluating our on-going core operating results.